|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions显示文摘AIM To quantify drug-drug-interactions(DDIs) encountered in patients prescribed hepatitis C virus(HCV) treatment, the interventions made, and the time spent in this process.METHODS As standard of care, a clinical pharmacist screened for DDIs in patients prescribed direct acting antiviral(DAA) HCV treatment between November 2013 and July 2015 at the University of Colorado Hepatology Clinic. HCV regimens prescribed included ledipasvir/sofosbuvir(LDV/SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir(OBV/PTV/r + DSV), simeprevir/sofosbuvir (SIM/SOF), and sofosbuvir/ribavirin (SOF/RBV). This retrospective analysis reviewed the work completed by the clinical pharmacist in order to measure the aims identified for the study. The number and type of DDIs identified were summarized with descriptive statistics.RESULTS Six hundred and sixty four patients(83.4% Caucasian, 57% male, average 56.7 years old) were identified; 369 for LDV/SOF, 48 for OBV/PTV/r + DSV, 114 for SIM/SOF, and 133 for SOF/RBV. Fifty-one point five per cent of patients were cirrhotic. Overall, 5217 medications were reviewed (7.86 medications per patient) and 781 interactions identified (1.18 interactions per patient). The number of interactions were fewest for SOF/RBV (0.17 interactions per patient) and highest for OBV/PTV/r + DSV (2.48 interactions per patient). LDV/SOF and SIM/SOF had similar number of interactions (1.28 and 1.48 interactions per patient, respectively). Gastric acid modifiers and vitamin/herbal supplements commonly caused interactions with LDV/SOF. Hypertensive agents, analgesics, and psychiatric medications frequently caused interactions with OBV/PTV/r + DSV and SIM/SOF. To manage these interactions, the pharmacists most often recommended discontinuing the medication (28.9%), increasing monitoring for toxicities (24.1%), or separating administration times (18.2%). The pharmacist chart review for each patient usually took approximately 30 min, with additional time for more complex patients. CONCLUSION DDIs are common with HCV medications and management can require medication adjustments and increased monitoring. An interdisciplinary team including a clinical pharmacist can optimize patient care. | Jacob A Langness Matthew Nguyen Amanda Wieland Gregory T Everson Jennifer J Kiser | 2017 | World Journal of Gastroenterology2017，23，9： | 5 |
| 2 | Efficient transfer for a glyphosate tolerance gene into tomato using a binary Agrobacterium tumefaciens vector显示文摘 | FILLATTI J J KISER J ROSE R | 1987 | Bio/Technology1987，5，： | 1 |
| 3 | Evidence - Based Practice in Child and Adolescent Mental Health Services 显示文摘 | Hoagwood K Burns B J Kiser L etc | 2001 | Psychiatric Service2001，，9： | 1 |
| 4 | Evaluation of ultra-high temperature ceramics foraeropropulsion use显示文摘 | Levine SR Opila E J Halbig MC Kiser JD Singh M Salem JA | 2002 | Journal of the European Ceramic Society2002，22，1415： | 1 |
| 5 | Spectroscopic investigation of Cr( Ⅲ ) -and Cr( VI ) -treated nanoscale zerovalent iron显示文摘 | Manning B A Kiser J R Kwon H | 2007 | Environ SciTechnot2007，41，2： | 1 |
| 6 | A perspective on the use of antibiotics in animal feeds 显示文摘 | KISER J S | 1976 | J Anim Sci1976，42，4： | 1 |
| 7 | Outcomes associ- ated with corticosteroid dosage in critically patients with acute exacerbations of chronic obstructive pulmonary dis- ease显示文摘 | Kiser TH Allen RR Valuck R J | 2014 | Am JRespir Crit Care Med2014，189，9： | 1 |
| 8 | An essential role for the Cdc6 protein in forming the pre-replication complexes of budding yeast 显示文摘 | Kiser G L Hartwell L H | 1996 | Nature1996，379，： | 1 |
| 9 | High-performance Liquid Chromatography Procedure for the Determination of Flavor Enhancers in Consumer Chocolate Products and Artificial Flavors显示文摘 | RISNER C H KISER M J | 2008 | J Sci Food Agric2008，88，8： | 1 |
| 10 | Efficient transfer of a glyphosate tolerance gene into tomato using a binary Agrobacterium tumefaciens vetor 显示文摘 | FILLATFI J J KISER J ROSE R | 1987 | Nature Biotechnology1987，5，： | 1 |
| 11 | Determination of the Backbone Structure of Nucleic Acids and Nucleic Acid Oligomers by Laser Raman Scattering显示文摘 | ERFURTH S C KISER E J PETICOLAS W L | 1972 | Proceedings of the National Academy of Sciences of the United States of America1972，69，4： | 1 |
| 12 | Spectroscopic investigation of Cr(Ⅲ)and Cr(Ⅵ)treated nanoscale zerovalent iron显示文摘 | Manning B A Kiser J R Kwon H | 2007 | Environ Sci Technol2007，41，： | 1 |
| 13 | Gold mineralization in high-grade metamorphic shear zones of the Renco Mine,Southern Zimbabwe 显示文摘 | Kisers A F M Kolb J Meyer F M | 1998 | Economic Geology1998，93，： | 1 |
| 14 | Efficient transfer of a glyphosme tolerance gene into to-mato using a binary Agrobacterium Tumefaciens Vector显示文摘 | Joanne J Fillatti John Kiser Ronald Rose Luca Co-mai | 1987 | Nature Biotechnology1987，，5： | 1 |
| 15 | Spectroscopic investigation of Cr( III)- and Cr(VI)-treated nanoscale zerovalent iron 显示文摘 | Manning B A Kiser J R Kwon H | 2007 | Environmental Science & Technology2007，41，2： | 1 |
| 16 | Evaluation of ultra-high temperature ceramics foraeropropulsion use显示文摘 | Stanley R Levine Elizabeth J Opila Michael C Halbig James D Kiser Mrityunjay Singh Jonathan A Salem | 2002 | Journal of the European Ceramic Society2002，，14： | 1 |
| 17 | Reduction and immobilization of chromium(Ⅵ)by iron(Ⅱ)-treated faujasite显示文摘 | Kiser J R Manning B A | 2010 | Journal of Hazardous Materials2010，174，13： | 1 |
| 18 | Reduction and immobilization of chromi- um(VI)by iron( II ) treated faujasite显示文摘 | J R Kiser B A Manning | 2010 | Journal of Hazardous Materi- als2010，174，13： | 1 |
| 19 | Thernloacoustic CT: Imaging Principles 显示文摘 | KRUGER R A KISER J R M II LER K D ct al | 2000 | Proc SPIE2000，3916，： | 1 |
| 20 | Evaluation of ultra-high temperature ceramics foraeropropulsion use显示文摘 | Stanley R Levine Elizabeth J Opila Michael C Halbig James D Kiser Mrityunjay Singh Jonathan A Salem | 2002 | Journal of the European Ceramic Society2002，，14： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员